Andelyn Biosciences, Inc., a forward-thinking Contract Development and Manufacturing Organization (CDMO) with a strong focus on patient-centric cell and gene therapy, has forged a strategic partnership with The Ohio State University Gene Therapy Institute to collaboratively advance the development and clinical production of innovative gene therapies.

This collaboration has been established with the aim of expediting the progress of Ohio State's experimental gene therapies for various neurological disorders, such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, from concept to clinical trial manufacturing. The Principal Investigators at Ohio State will leverage Andelyn's expertise, which encompasses their adherent and suspension platforms, extensive experience in viral vector development, process optimization, and comprehensive manufacturing capabilities. The joint effort between Ohio State and Andelyn is designed to enhance operational efficiencies and accelerate the path to clinical application.

The collaborative development of novel gene therapies further strengthens the ongoing partnership between Ohio State and Andelyn and holds promising prospects for patients grappling with genetically-rooted neurological conditions. The robust collaboration between both institutions is aimed at ensuring the rapid and high-quality delivery of Ohio State's gene therapies to patients in need.

Andelyn, expressed, "We are honored to play a pivotal role as a crucial resource for Ohio State's esteemed Gene Therapy Institute, supporting groundbreaking gene therapy initiatives through our pre-clinical and GMP manufacturing capabilities."

Dr. Russell Lonser, Director of Ohio State's Gene Therapy Institute, noted, "There is a pressing imperative to develop effective treatments for ALS, Huntington's disease, and Parkinson's disease. We believe that gene therapy holds the promise of offering new hope to those afflicted by these debilitating neurological disorders and eagerly anticipate the accelerated development of transformative therapies."

With Andelyn's Good Manufacturing Practice (GMP) manufacturing capabilities now firmly established at their state-of-the-art Andelyn Corporate Center (ACC), spanning 180,000 square feet, Andelyn is pleased to provide its clients with exceptional quality and large-scale suspension clinical and commercial manufacturing within the biotechnology hub of Columbus, Ohio. The ACC complements Andelyn's two other facilities in Columbus, which focus on pre-clinical process development and plasmid manufacturing.

 

Source: prnewswire.com

Report Abuse